23 results
DEF 14A
NMRA
Neumora Therapeutics Inc.
25 Apr 24
Definitive proxy
4:05pm
and vision benefits; medical and dependent care flexible spending accounts; short-term and long-term disability insurance; and life and AD&D insurance. Our … NEOs are eligible for certain enhanced benefits under our executive-level medical insurance, life insurance and short-term and long-term disability
10-K
2023 FY
NMRA
Neumora Therapeutics Inc.
7 Mar 24
Annual report
4:05pm
replicate Phase 3 studies, KOASTAL-1, KOASTAL-2 and KOASTAL-3 as well as an open-label extension study, KOASTAL-LT, designed to evaluate the long-term safety … . KOASTAL-LT (Study 501) will be a long-term safety extension study. All studies in the KOASTAL program are underway. All three efficacy studies
8-K
EX-99.1
NMRA
Neumora Therapeutics Inc.
8 Jan 24
Regulation FD Disclosure
8:32am
in 1H25 expected in 1H25 Long-term data enables Planned 1H24 Stress Disorder NDA submission in 2025 Initiation MDD = Major Depressive Disorder; RCT … in patients with MDD. Approach Open-label extension Placebo-controlled RCT provides increased probability of success across program. trial evaluating long
10-Q
2023 Q3
NMRA
Neumora Therapeutics Inc.
1 Nov 23
Quarterly report
4:05pm
Restricted cash
Prepaid expenses and other current assets
Total current assets
Long-term marketable securities
Property and equipment, net
Operating … . The Company will need to raise additional capital to support its continuing operations and pursue its long-term business plan, including to complete
8-K
EX-99.1
ke9bfyc
1 Nov 23
Neumora Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
4:01pm
S-8
EX-99.3
yzeseofo
19 Sep 23
Registration of securities for employees
9:57pm
424B4
nzwu6zd4wnyfvkgf
18 Sep 23
Prospectus supplement with pricing info
4:12pm
S-1/A
4q5zz
11 Sep 23
IPO registration (amended)
6:07am
S-1/A
EX-1.1
vw554w
11 Sep 23
IPO registration (amended)
6:07am
S-1
EX-10.7
n2fhlcz4huovu
25 Aug 23
IPO registration
5:03pm
S-1
2c5s42g0ou 0h0
25 Aug 23
IPO registration
5:03pm
S-1
EX-10.20
pr22r5a21cwp6hhf
25 Aug 23
IPO registration
5:03pm
DRS/A
pqmi08q
9 Aug 23
Draft registration statement (amended)
12:00am
DRS/A
EX-10.21
b861re
9 Aug 23
Draft registration statement (amended)
12:00am
DRSLTR
zf9z7pu168m9srg569
30 Jun 23
Correspondence regarding draft registration statement
12:00am
DRS/A
gkiy7
30 Jun 23
Draft registration statement (amended)
12:00am
DRS/A
i50htr3 14rsdd2
2 May 23
Draft registration statement (amended)
12:00am
DRS/A
0bcz 9ew083n
2 Sep 22
Draft registration statement (amended)
12:00am
DRS/A
ktoajcpovb hwxheztj
10 Jun 22
Draft registration statement (amended)
12:00am